N
Norbert Ahrens
Researcher at University Hospital Regensburg
Publications - 61
Citations - 1489
Norbert Ahrens is an academic researcher from University Hospital Regensburg. The author has contributed to research in topics: Extracorporeal Photopheresis & Autoimmune hemolytic anemia. The author has an hindex of 21, co-authored 58 publications receiving 1226 citations. Previous affiliations of Norbert Ahrens include Free University of Berlin & Charité.
Papers
More filters
Journal ArticleDOI
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
Birgit Sawitzki,Paul N. Harden,Petra Reinke,Aurélie Moreau,James A. Hutchinson,David Game,Qizhi Tang,Eva C. Guinan,Manuela Battaglia,William J. Burlingham,Ian S.D. Roberts,Mathias Streitz,Régis Josien,Carsten A. Böger,Cristiano Scottà,James F. Markmann,Joanna Hester,Karsten Juerchott,Cécile Braudeau,Ben James,Ben James,Laura Contreras-Ruiz,Jeroen B. van der Net,Tobias Bergler,Rossana Caldara,William Petchey,Matthias Edinger,Matthias Edinger,Nathalie Dupas,Michael Kapinsky,Ingrid Mutzbauer,Ingrid Mutzbauer,Natalie M Otto,Robert Öllinger,Maria P. Hernandez-Fuentes,Fadi Issa,Norbert Ahrens,Christoph Meyenberg,Sandra Karitzky,Ulrich Kunzendorf,Stuart J. Knechtle,Josep M. Grinyó,Peter J. Morris,Peter J. Morris,Leslie Brent,A. Bushell,Laurence A. Turka,Jeffrey A. Bluestone,Robert I. Lechler,Hans J. Schlitt,M. C. Cuturi,Stephan Schlickeiser,P Friend,Tewfik Miloud,Alexander Scheffold,Antonio Secchi,Kerry Crisalli,Sang-Mo Kang,Rachel Hilton,Bernhard Banas,Gilles Blancho,Hans-Dieter Volk,Giovanna Lombardi,Kathryn J. Wood,Edward K. Geissler,Edward K. Geissler,Edward K. Geissler +66 more
TL;DR: In this paper, the authors evaluated the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment in kidney transplant patients and found that CBMP is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year.
Journal ArticleDOI
TIGIT + iTregs elicited by human regulatory macrophages control T cell immunity
Paloma Riquelme,Jan Haarer,Anja Kammler,Lisa Walter,Stefan Tomiuk,Norbert Ahrens,Anja K. Wege,Ivan Goecze,Daniel Zecher,Bernhard Banas,Rainer Spang,Fred Fändrich,Manfred B. Lutz,Birgit Sawitzki,Hans J. Schlitt,Jordi Ochando,Edward K. Geissler,James A. Hutchinson +17 more
TL;DR: It is shown that human Mreg convert allogeneic CD4+ T cells to IL-10-producing, TIGIT+ FoxP3+-induced regulatory T cells that non-specifically suppress bystander T cells and inhibit dendritic cell maturation, and that donor Mreg-induced recipient Tregs may promote kidney transplant acceptance in patients.
Journal ArticleDOI
Heat shock protein 70 (Hsp70) peptide activated Natural Killer (NK) cells for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCTx) - from preclinical studies to a clinical phase II trial
Hanno M. Specht,Norbert Ahrens,Christiane Blankenstein,Thomas Duell,Rainer Fietkau,Udo S. Gaipl,Christine Günther,Sophie Gunther,Gregor Habl,Hubert Hautmann,Matthias G. Hautmann,Rudolf M. Huber,Michael Molls,Robert Offner,Claus Rödel,Franz Rödel,Martin Schütz,Stephanie E. Combs,Gabriele Multhoff +18 more
TL;DR: The primary objective of this multicenter proof-of-concept trial is to examine whether an adjuvant treatment of NSCLC patients after platinum-based radiochemotherapy (RCTx) with TKD/IL-2 activated, autologous NK cells is clinically effective.
Journal ArticleDOI
Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab).
Journal ArticleDOI
Coexistence of autoantibodies and alloantibodies to red blood cells due to blood transfusion.
TL;DR: Alloantibodies to red blood cells (RBCs) are frequently associated with alloantIBodies (ALLO) and the mechanism for the coexistence of these antibodies is obscure.